GLP-1类似物艾塞那肽研究进展 |
| |
引用本文: | 侯书杰,才丽,李克剑,孙欧希.GLP-1类似物艾塞那肽研究进展[J].中国执业药师,2013,10(7):38-39,53. |
| |
作者姓名: | 侯书杰 才丽 李克剑 孙欧希 |
| |
作者单位: | 侯书杰 (吉化集团公司总医院二院,吉林,吉林,132022); 才丽 (吉化集团公司总医院二院,吉林,吉林,132022); 李克剑 (吉化集团公司总医院二院,吉林,吉林,132022); 孙欧希 (吉化集团公司总医院二院,吉林,吉林,132022); |
| |
摘 要: | 胰高血糖素样肽-1类似物艾塞那肽是一种全新作用机制的降糖药物,具有降低血糖而不引起低血糖且有降低体质量的作用,还具有心血管保护作用和抑制乳腺癌细胞增长作用。本文对艾塞那肽近期的国内外文献进行分析,从其临床应用研究、新剂型研究、安全性等方面阐述其研究进展。
|
关 键 词: | 艾塞那肽 胰高血糖素样肽-1类似物 降糖药物 研究进展 不良反应 |
Research Progress of Glucagon-like Peptide-1 Analogue Exenatide |
| |
Authors: | Hou Shujie Cai Li Li Kejian Sun Ouxi |
| |
Affiliation: | (The Second Hospital of the General Hospital of Jilin Chemical Group Company, Jilin Jilin 132022, China) |
| |
Abstract: | Glucagon-like peptide-1 (GLP-1) analogue exenatide is a new type of antidiabetic drug with a new action mechanism. It can lower blood sugar without causing hypoglycemia and reduce body weight. It has cardiovascular protective effects and can inhibit breast cancer cell growth. In this paper the recent literatures about the exenatide both at home and abroad were reviewed and analyzed and the research progress on the clinical application, the new form preparation and safety, etc. was introduced. |
| |
Keywords: | Exenatide Glucagon-like Peptide-1 Analogue Antidiabetic Drugs Research Progress Adverse Reaction |
本文献已被 维普 等数据库收录! |
|